Evaluating Efalizumab for Psoriasis Treatment
Author Information
Author(s): Kim A Papp, Eric Henninger
Primary Institution: Probity Medical Research
Hypothesis
The study aims to assess the benefit:risk of efalizumab for treating moderate-to-severe plaque psoriasis using the Safe Psoriasis Control measure.
Conclusion
Efalizumab has a favorable benefit:risk profile using the comprehensive outcome measure Safe Psoriasis Control.
Supporting Evidence
- 39.4% of patients achieved Safe Psoriasis Control after 12 weeks of treatment with efalizumab compared to 10.4% for placebo.
- In high-need patients, 33.0% achieved Safe Psoriasis Control on efalizumab compared to 3.4% on placebo.
Takeaway
Efalizumab helps many people with psoriasis feel better without causing major side effects.
Methodology
The study applied the Safe Psoriasis Control measure to data from four placebo-controlled clinical studies of efalizumab.
Potential Biases
Potential bias due to the involvement of authors with ties to the pharmaceutical company.
Limitations
The study's findings may not be generalizable beyond the specific patient populations studied.
Participant Demographics
Patients aged 18 to 75 with moderate-to-severe plaque psoriasis covering at least 10% of total body surface area.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website